Applying rapid 'de-facto' HTA in resource-limited settings: Experience from Romania

Health Policy

Volumn 112, Issue 3, 2013, Pages 202-208

  Lopert, Ruth ^a   Ruiz, Francis ^b   Chalkidou, Kalipso ^b  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

Author keywords

Access to medicines; Cost effectiveness; Drug pricing; Health technology assessment; Reference pricing

Indexed keywords

ADALIMUMAB; ATORVASTATIN; BORTEZOMIB; CAPECITABINE; CLOPIDOGREL; DONEPEZIL; ETANERCEPT; ETIRACETAM; FENOFIBRATE; IMATINIB; INFLIXIMAB; INSULIN GLARGINE; INSULIN LISPRO; MEMANTINE; MONTELUKAST; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OLANZAPINE; OMEPRAZOLE; PEGINTERFERON ALPHA2A; PERINDOPRIL; QUETIAPINE; RECOMBINANT ERYTHROPOIETIN; RIVASTIGMINE; ROSUVASTATIN; SIMVASTATIN; TRASTUZUMAB; ZOLEDRONIC ACID;

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH TECHNOLOGY ASSESSMENT; HUMAN; REIMBURSEMENT; ROMANIA; UNITED KINGDOM;

ACCESS TO MEDICINES; COST EFFECTIVENESS; DRUG PRICING; HEALTH TECHNOLOGY ASSESSMENT; REFERENCE PRICING;

CAPACITY BUILDING; COST-BENEFIT ANALYSIS; DECISION MAKING; DRUG COSTS; HEALTH CARE RATIONING; HEALTH POLICY; HEALTH RESOURCES; HEALTH SERVICES ACCESSIBILITY; HUMANS; PHARMACOPOEIAS AS TOPIC; ROMANIA; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84887074987     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2013.07.019     Document Type: Article

References (30)

1. Priority-Setting in Health: Building Institutions for Smarter Public Spending. A report of the Center for Global Development's Priority Setting Institutions for Global Health Working Group. Available at: http://www.cgdev.org/content/publications/detail/1426240/.
2. For example, Greece and Spain have recently implemented substantial price cuts for both patented and generic medicines and India recently awarded a compulsory licence for the drug Nexavar - a move that reduced the price by 97%. See [last accessed 15.08.12]. http://www.rttnews.com/1838869/natco-gets-compulsory-license-for-nexavar.aspx.
3. Howitt P., Darzi A., Guang-Zhong, Atun R., Barlow J., et al. Technologies for global health. Lancet 2012, 380:507-535.
4. The Pan American Health Organisation (PAHO) has urged its member states to incorporate decision making processes based on HTA. See 150th Session of the Executive Committee. Health Technology Assessment and Incorporation into Health Systems - Resolution CE150.R17. Pan American Health Organization, Washington, June 2012. Available at: [last accessed 15.08.12]. http://new.paho.org/hq/index.php.
5. See: and [last accessed 15.08.12]. http://www.anvisa.gov.br/eng/index.htm.
6. Augustovski F., Melendez G., Lemgruber A., Drummond M. Implementing pharmacoeconomic guidelines in Latin America: lessons learned. Value in Health 2011, 14:S3-S7.
7. Oortwijn W., Mathijssen J., Banta D. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries. Health Policy 2010, 95:174-184.
8. Chalkidou K., Levine R., Dillon A. Helping poorer countries make locally informed health decisions. BMJ 2010, 341:c3651.
9. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Quality and Safety in Health Care 2003, 12:18-23. AGREE Collaboration, [last accessed 15.08.12]. http://www.adapte.org/www/rubrique/the-%20adapte-collaboration.php.
10. Fervers B., Burgers J.S., Haugh M.C., Latreille J. Adaptation of clinical guidelines: literature review and proposition for a framework and procedure. International Journal for Quality in Health Care 2006, 18:167-176.
11. Chase D., Rosten C., Turner S., Hicks N., Milne R. Development of a toolkit and glossary to aid in the adaptation of health technology assessment (HTA) reports for use in different contexts. Health Technology Assessment 2009, 13(59):1-142.
12. Anderson R. Systematic reviews of economic evaluations: utility or futility?. Health Economics 2010, 19:350-364.
13. Belciu B., Cretu A. Romanian pharmaceutical market - current challenges and expected development. PwC Romania 2012, (April). Available at:, [last accessed 15.08.12]. http://rbd.%20doingbusiness.%20ro/en/10/latest-articles/1/746/romanian-pharmaceutical-market-current-challenges-and-%20expected-development.
14. Seiter A Romania: Pharmaceutical Sector Analysis. World Bank, 2007. Available at: [last accessed 15.08.12]. http://apps.who.int/medicinedocs/en/m/abstract/Js16762e/.
15. Çelik Y, Seiter A. Turkey: Pharmaceutical Sector Analysis. (Ankara, World Bank, 2008). Available at: [last accessed 15.08.2]. http://apps.who.int/medicinedocs/en/m/abstract/Js16766e/.
16. Lopert R., Lang D.L., Hill S.R., Henry D.A. Differential pricing of drugs: a role for cost- effectiveness analysis?. Lancet 2002, 359(9323):2105-2107.
17. See: for NICE Technology Appraisals for BNF [last accessed 15.08.12]. http://www.bnf.org/bnf/index.htm.
18. See [last accessed 15.08.12]. http://www.ceepharma.com/103774/ARPIM-outstanding-payments-for-drug-%20reimbursement-to-lead-to-limit-drug-choice-in-Romania.shtml.
19. Yadav P. Differential pricing for pharmaceuticals: review of current knowledge, new findings and ideas for action. MIT-Zaragoza International Logistics Program, for a DFID workshop and analysis 2010, Available at:, [last accessed 15.08.12]. http://www.dfid.gov.uk/Documents/publications1/prd/diff-%20pcing-pharma.pdf.
20. Dranitsaris G., Ortega A., Lubbe M.S., Truter I. A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe. Journal of Oncology Pharmacy Practice 2012, 18(1):57-67.
21. Towse A., Devlin N., Hawe E., Garrison L. The evolution of HTA in emerging markets health care systems: analysis to support a policy response 2011, Office of Health Economics Consulting Report, At:, [last accessed 15.08.12]. http://www.ohe.org/publications/article/the-evolution-of-%20hta-in-emerging-markets-100.cfm.
22. See [last accessed 15.08.12]. https://www.wp.dh.gov.uk/transparency/files/2012/07/MISG-meeting-11-July-%202012-Letter-to-Secretary-of-State-about-NICE-Technology-Appraisals.pdf.
23. Morgan S., Hanley G., McMahon M., Barer M. Influencing drug prices through formulary-based policies: lessons from New Zealand. Healthcare Policy 2007, 3(1):1-20.
24. Costa Font J., Kanavos P. Medicines parallel trade in the European Union: a gravity specification. LSE Health 2007, (March). Working Paper No: 6/2007.
25. See World Bank. World Development Report. (World Bank; Washington, DC: 1993); and WHO. Cost effectiveness thresholds by region: [last accessed 15.08.12]. http://www.who.int/choice/costs/CER_thresholds/en/index.html.
26. Ngorsuraches S., Meng W., Kim B.-Y., Kulsomboon V. Drug reimbursement decision-making in China, Thailand and South Korea. Value in Health 2012, 15:S120-S125.
27. Megget K. Per capita income-linked reference pricing planned for India. Pharma Times Online 2012, Available at, [last accessed 20.08.12]. http://www.pharmatimes.com/Article/12-08-17/Per_capita_income-linked_reference_pricing_planned_for_India.aspx.
28. Sculpher M., Claxton K. Real economics needs to reflect real decisions: a response to Johnson. Pharmacoeconomics 2012, 30(2):133-136.
29. Ruiz F., Lopert R., Chalkidou K. Technical assistance in reviewing the content and listing processes for the romanian basic package of health services and technologies: final report. NICE International January 2012, Available at:, [last accessed 15.08.12]. http://tinyurl.com/8gm7qjf.
30. See [last accessed 15.08.12]. http://www.imf.org/external/np/loi/2012/rou/060812.pdf.